Haematology Patient and Carers Congress (HPCC)

Dear BOPA Members,

Please share with your patients, their families, carers, and colleagues….

A first ever, cross-disease site, Haematology Patient and Carers Congress (HPCC) 2024, is being held at the Queen Elizabeth II Centre in Westminster, London on May 10th, 2024. 

Patients will be able to connect with one another through a range of interactive workshops, informative clinical presentations, and powerful story-telling sessions.  The agenda has been specifically curated by Patients, Charities, Patient Organisations, and a Clinical Advisory Board co-chaired by Professor Claire Harrison, GSTT, and Dr Shirley D’Sa, UCLH.

Multi-disciplinary speakers include Professor Adele Fielding- Professor of Haematology, Professor Mhairi Copland- Professor of Translational Haematology, Nick Duncan- Consultant Haematology Pharmacist, Professor Stephen Powis- National Medical Director NHSE, Sir James Mackey- National Director of Elective Recovery, Jenna Tate- Advanced Clinical Practitioner in Haematology, Orla McCourt- Clinical Academic Physiotherapist, and more.

The event is free of charge. To ensure accessibility and equity for all patients, if patients require assistance with travel and accommodation arrangements, advise them to email [email protected]. Assistance will be provided on a first-come, first-served basis, with priority given to urgent needs.

All patients affected by a haematological condition are welcome. NHS staff are also welcome to attend.  Please find useful links below:

  1. HPCC Website – please click here
  2. HPCC Sign up Link (Patients/ Carers/ Families) – please click here
  3. HPCC Sign up Link (NHS staff)- Registration Link

Latest News

By BOPA Research Committee on 27th April 2025

SURVEY: Understanding Clinicians’ perceptions of a Decision Support tool for Lung Cancer Treatment

Dear BOPA member, Tarini Deleep and Dr Pinkie Chambers from University College London are developing a risk prediction model to help identify patients with incurable Non Small Cell Lung Cancer,…

Read article
By BOPA on 27th April 2025

Further monographs for use of immunosuppressants in Immune-related adverse events (irAEs)

Earlier this year the BOPA Immunotherapy Group wrote, and published, four monographs to help health care professionals care for patients with immune-related adverse events. As a group we are pleased…

Read article
By BOPA Committee on 27th April 2025

Women for Oncology UK Spring Webinar

The Spring webinar for Women for Oncology UK is on the 16th May, to sign up click the link below. Women For Oncology UK Spring Webinar Tickets, Wed 14 May…

Read article
By BOPA Executive Committee on 25th April 2025

NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.

BOPA have been involved with the following NICE TA: Ribociclib with an aromatase inhibitor can be used as an option for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer…

Read article